Navigation Links
The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial
Date:12/3/2008

WHITE PLAINS, N.Y., Dec. 3 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Memgen, LLC jointly announce the beginning of a new clinical trial of ISF35, a cancer vaccine, at the University of California, San Diego (UCSD).

LLS is collaborating on this trial in the hopes that it will speed the development and approval of a novel approach aimed at treating patients with fludarabine refractory and/or 17p deleted chronic lymphocytic leukemia (CLL).

Doctors at UCSD have already begun treating the first patient with ISF35. They plan to enroll up to twelve patients. These patients will receive a vaccine expressing an immune-boosting molecule, ISF35 (Immune Stimulatory Factor 35), followed by three courses of rituximab plus the chemotherapy drugs fludarabine and cyclophosphamide (FCR).

"This clinical study builds upon three previous trials already completed at M.D. Anderson and here at UCSD," said Januario E. Castro, M.D., assistant clinical professor at the UCSD School of Medicine and the Moores Cancer Center, who leads the work. "Those trials showed remarkable results for ISF35 in patients with high risk and treatment-resistant CLL. Most importantly, ISF35 was well-tolerated with only minimal side effects, reduced CLL cells and lymph nodes in nearly every patient, and when combined with chemotherapy produced complete or partial remissions in patients with 17p deleted CLL."

"There is a clear unmet medical need for new therapies to treat refractory or relapsed CLL, and in particular 17p- patients," said Louis J. DeGennaro, Ph.D., LLS's chief scientific officer. "Our goal is to bring new treatment options to these patients quickly."

For more information about participating in this clinical trial, contact Denise Darrah, at the Moores UCSD Cancer Center, 858-822-5375, or ddarrah@ucsd.edu or the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

About Memgen, LLC

Memgen is a clinical stage biotechnology company with offices in Dallas and San Diego. Memgen was founded four years ago to develop non-toxic and targeted active immunotherapies for the treatment of cancers. Its lead product, ISF35, has demonstrated potent anti-leukemic activity as a single agent and is well-tolerated. ISF35 generates none of the immunosuppressive activities associated with standard cancer treatments.

For more information about Memgen, visit www.memgenbio.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

    LLS Contact: Andrea Greif
    914.821.8958
    andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse
3. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
4. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
7. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
8. Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
9. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016 /PRNewswire/--  ... have announced that advanced tissue-engineering services are now ... using a groundbreaking new three-dimensional (3D) bioprinting approach ... Regenova® 3D Bio Printer , a state-of-the-art robotic ... Applications has created a powerful pay-for-service bio-printing model ...
(Date:2/8/2016)... Feb. 8, 2016  Avista Pharma Solutions ("Avista Pharma") ... as Chief Financial Officer (CFO). Mr. Setzer is a ... experience in various roles within growing technology and life ... as the Executive Director of Finance at INC Research, ... Raleigh, NC . Previously, Mr. Setzer served as ...
(Date:2/8/2016)... 8, 2016 Velano Vascular, a medical technology ... patients and their practitioners, announced today that the company ... will use the proceeds from this financing, an extension ... January 2015, to support the development and commercialization of ... populations. Philadelphia , and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted February 8, ... West Awards. , Awards include the Information Security Executive® of the ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):